All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: Investigation with selective metabolic drug probes

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 2, 1997, Pages 133-139

  Adedoyin, Adedayo ^a,b,c   Stiff, Dwight D ^a,b   Smith, David C ^b,d   Romkes, Marjorie ^a,b,e   Bahnson, Robert C ^b,d   Day, Roger ^b,f   Hofacker, Janie ^d   Branch, Robert A ^a,b,d   Trump, Donald L ^b,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

All trans retinoic acid; Drug metabolism; Enzyme activities; Selective drug probes; Selective modulation

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CHLORZOXAZONE; CHLORZOXAZONE HYDROXYLASE; CYTOCHROME P450; DAPSONE; DEBRISOQUINE; MEPHENYTOIN; RETINOIC ACID; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

EID: 0031950724     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050719     Document Type: Article

References (42)

1. Atiba JO, Manzardo AM, Thiruvengadan R, Schell M (1995) Effect of drug holiday on tRA pharmacokinetics. Clin Pharmacol Ther 57: 152
2. Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237
3. Breitmann T, Selenick S, Collins S (1980) Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936
4. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood 76: 1704
5. Chen Z-X, Xue Y-Q, Zhang R, Tao R-F, Xia X-M, Li C, Wang W, Zu W-Y, Yao X-Z, Ling B-J (1991) A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78: 1413
6. Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K (1993) Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 53: 2100
7. Frye RF, Branch RA (1996) Improved high performance liquid Chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. J Chromatogr 677: 178
8. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the "Pittsburgh Cocktail" approach to assess selective regulation of drug metabolizing enzymes. Clin Pharmacol Ther (in press)
9. Frye RF, Stiff DD, Branch RA, Matzke GR (1996) A sensitive method of simultaneous determination of caffeine and its dimethylxanthine metabolites in human plasma and saliva. J Chromatogr (in press)
10. Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4: 109
11. Gibson GG (1994) Peroxisome proliferators and CYP4A induction. Proceedings. Tenth International Symposium on Microsomes and Drug Oxidation, Toronto, Ontario, Canada 1994. p 65
12. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347: 773
13. Guengerich FP, Kim D-H, Iwasaki M (1991) Role of cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168
14. Huang M-E, Ye Y-C, Chen S-R, Chai J-R, Lu J-Z, Zhoa L, Gu L-J, Wang Z-Y (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567
15. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, Branch RA (1987) Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47: 5488
16. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC (1992) Cytochrome P4502E1 genetic polymorphism, racial variation and lung cancer. Cancer Res 52: 6712
17. Kelly WK, Scher HI, Muindi J, Bajorin D, O'Moore P, Renter V, Young CW, Curley T, Liebertz C (1993) Phase II trial of all-trans retinoic acid in patients with adenocarcinoma. Proc Annu Meet Am Soc Clin Oncol 34: 1210
18. Koeffler H (1986) Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 62: 709
19. Leo MA, Iida S, Lieber CS (1984) Retinoic acid metabolism by a system reconstituted with cytochrome P-450. Arch Biochem Biophys 234: 305
20. May G, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA (1990) The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 48: 619
21. May DG, Arns PA, Richards WO, Porter JA, Ryder D, Fleming CM, Wilkinson GR, Branch RA (1992) Influence of cirrhosis on the disposition of dapsone. Clin Pharmacol Ther 51: 689
22. Muindi JRF, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RP Jr (1992) Clinical pharmacology of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52: 2138
23. Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr (1992) Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79: 299
24. Muindi JF, Young CW (1993) Lipid hydroperoxides greatly increase the rate of oxidutive catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 53: 1226
25. Phillip PA, Harper PC, Rogers HJ (1989) Effect of cancer chemotherapy on dapsone N-acetylation in man. Cancer Chemother Pharmacol 23: 395
26. Rigas JR, Francis PA, Muindi JRF, Kris MG, Huselton C, DeGrazia F, Orazem JP, Young CW, Warrell RP Jr (1993) Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 85: 1921
27. Roberts AB, Lamb LC, Sporn MB (1980) Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy- to 4-keto-retinoic acid. Arch Biochem Biophys 199: 374
28. Sato M, Lieber CS (1982) Increased metabolism of retinoic acid after chronic ethanol consumption in rat liver microsomes. Arch Biochem Biophys 213: 517
29. Shapiro S (1986) Retinoids and epithelial differentiation. In: Sherman M (ed) Retinoids and cell differentiation. CRC Press, Boca Raton, pp 25-59
30. Smith MA, Adamson PC, Balis FM, Feusner J, Aromson L, Murphy RF, Horowitz ME, Reaman G, Hammond GD, Fenton RM, Connaghan GD, Hiettelman WN, Poplack DG (1992) Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10: 1666
31. Stiff DD, Frye RF, Branch RA (1993) Sensitive high-performance liquid Chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. J Chromatogr 613: 127
32. Trump DL (1994) Retinoids in bladder cancer, testis and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 8: S50
33. Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Whiteside T, Bahnson RC, Hofacker J, Branch RA (1997) A phase two trial of all-transretinoic acid in hormone refractory prostate cancer: a clinical trial with detailed pharmacokinetic study. Cancer Chemother Pharmacol 39: 349
34. Van Wauwe JP, Coene MC, Goossens J, Van Nyen G, Cools W, Lauwers W (1988) Ketoconazole inhibits the in vitro and in vivo metabolism of all-transretinoic acid. J Pharmacol Exp Ther 245: 718
35. Van Wauwe JP, Coene MC, Goosens J, Cools W, Monbaliu J (1990) Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-transretinoic acid in rats. J Pharmacol Exp Ther 252: 365
36. Van Wauwe J, Van Nyen G, Coene MC, Stoppie P, Cools W, Goossens J, Borghgraef P, Janssen PAT (1992) Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 261: 773
37. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Price Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5: 1
38. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-transretinoic acid). New Engl J Med 324: 1385
39. Wedlund PJ, Aslanian WA, Jacqz E, McAllister CB, Wilkinson GR, Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36: 773
40. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR (1984) Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 307: 121
41. Williams JB, Napoli JL (1985) Metabolism of retinoic acid and retinol during differentiation of F9 embryonal cells. Proc Natl Acad Sci USA 82: 4658
42. Williams JB, Napoli JL (1987) Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells. Biochem Pharmacol 36: 1386